Organon Audit Committee completes biosimilar purchase review, finds no improper conduct

Organon & Co.

Audit Committee completed independent review of timing of biosimilar purchases from a supplier in prior years.
Review found no evidence of improper conduct and no adjustments to previously issued financial statements.
Company intends to file its Form 10-K for the year ended December 31, 2025 on time.
No changes required to SEC disclosures related to the transactions reviewed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.